KeratOPrinter Advanced 4D Printing Technologies in Corneal Regeneration: A Pathway to Restored Vision
- Coordinator
- Tampereen Korkeakoulusaatio Sr, Finland
- Runs
- 1 January 2025 to 31 December 2029
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €8.0m
- Partners
- 10 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101191726
What the project is doing
In the project's own words, from its summary on CORDIS.
Corneal blindness is the 3rd leading cause of blindness globally, affecting >11.7mi people. Although the cornea is the most transplanted tissue, only 1-in-70 patients in need receive a cornea due to a severe shortage of donor tissue.3D bioprinting offers an attractive solution. However, existing technology cannot mimic the complexity of cornea tissue, which is necessary to reproduce its optomechanical & biological functionality.
The KeratOPrinter project thus, proposes a highly ambitious approach to develop a 4D bioprinting suite that can deliver a fully functional, biocompatible, full-thickness native-like human cornea. The consortium combines world-class partners to provide:a) An innovative & scalable cell source with high cell viability & native-like functionality in vivo for the different cell types in the cornea; b) Several multi-material bioink formulations which can reproduce the native-environment heterogeneity & extracellular matrix to deliver the optical, mechanical & biological functionality; c) Single-cell bioprinting resolution with µm accuracy & in-process monitoring for clinical-level quality control at viable printing speeds; d) Clinical handling technology for transportation, logistics & surgical implementation, supported by complementary implementation of multiple bioprinting technologies; e) GMP-compliant cell manufacturing and bioprinting technologies supported by in vivo & GLP studies for fast translation to the clinical environment; f) Early regulatory engagement augmented by a thorough regulatory and ethical analysis culminating in a comprehensive regulatory pathway to support future commercialisation and g) A dedicated community of researchers, clinicians, healthcare providers, regulatory and standardisation bodies, patient groups, technology developers, & industry to translate project results into targeted outcomes & long-term impacts.
Ultimately, KeratOPrinter aims to enable millions of people to receive vision-saving therapy by 2035.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Tampereen Korkeakoulusaatio Sr | Tampere | Finland | Coordinator |
| Cellbox Solutions | Koln | Germany | Participant |
| Klinikum Der Universitaet Zu Koeln | Koeln | Germany | Participant |
| Asphalion SL | Barcelona | Spain | Participant |
| Brinter Oy | Turku | Finland | Participant |
| Helsingin Yliopisto | Helsinki | Finland | Participant |
| Stemsight Oy | Tampere | Finland | Participant |
| Crowdhelix Limited | Cork | Ireland | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI